Despite the negative news and worrying headlines, we recommend traders to make mental reframing of the situation. This way, you can look at the market from a different perspective. Let’s observe how you can take advantage of the uncertainties and make the fundamentals work for you!
Optimistic vaccine news from Pfizer
Information is not investment advice
The coalition of Pfizer and BioNTech have announced that the regulatory review of the Covid-19 vaccine is scheduled for October. This positive news may add some tailwinds to the Pfizer stock.
Their vaccine is going through the second phase of trials in the USA and Germany now. According to Pfizer, the vaccine is “well tolerated with mild to moderate fever in fewer than 20%” of participants. It’s one of the fast-developing and promising vaccines as in July Pfizer and BioNTech have signed a deal with the US government to produce 100 million doses of its vaccine for 2 billion dollars. Companies are planning to reach same agreements with Canada, the UK and Japan. Some analysts believe this vaccine may be approved for use in the USA in November as a strategic move of Donald Trump during his re-election. If it really happens, it will make the vaccine of Pfizer and BioNTech a clear frontrunner. However, more realistic deadlines are set for the end of this year or early 2021.
Moreover, Pfizer has other successful products except from the vaccine such as Ibrance and Eliquis. Therefore, the company will prosper independently of the Covid-19 vaccine’s effectiveness. The pharmaceutical company has increased its dividend payments by 35.7% over the past 5 years. That made it a highly reliable company in the eyes of investors. Pay closer attention to BioNTech as Pifzer has lost 1% of its’ value since the beginning of this year, while BioNTech has surged by 95%.
Let’s look at the charts. Pfizer is trading just below the key resistance of $39.00. If it manages to cross it, it may jump to the psychological mark of $40.00. Otherwise, if it falls below the low of August 11 at $37.75, it may dip down to the 200-day moving average at $36.50.
Vaccine hopes may drive BioNTech above the close resistance of $71.50. If it rises above it, the way to the high of August 3 of $85.00 will be clear. On the flip side, if it drops below the low levels of early July at $63.00, it may slump to $58.00.
The US Federal Reserve may refrain from more aggressive interest rate hikes in March due to geopolitical risks after Russia's special operation in Ukraine…
Hello from the far 2022! FBS analysts have used some magic to travel to the future and brought you some hilarious predictions.
Japan's inflation is set to reach 2% in April's reading, for the first time since 2015. But what about the weaker Yen?!
Last week brought a selloff in markets. Some assets reached the most crucial support levels and are likely to reverse in a short term. Be ahead of trends and make the most out of this week!
Historically, the stability of the franc is caused by the solid Swiss economy and a highly developed banking system…